CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cougar Biotechnology, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cougar Biotechnology, Inc.
10990 Wilshire Blvd
Suite 1200
Phone: (310) 943-8040p:310 943-8040 Los Angeles, CA  90024  United States Ticker: CGRB CGRB
This company was Merged or Acquired on 7/9/2009.
This company ceased filing statements with the SEC on 7/10/2009.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Cougar Biotechnology, Inc. is a development-stage biopharmaceutical company that acquires and develops products for the treatment of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer, and then developing those drug candidates for commercial use. As of December 31, 2008, it had rights to three clinical-stage drug candidates: CB7630 (abiraterone acetate), which the Company is developing for the treatment of advanced prostate cancer and breast cancer; CB3304 (noscapine and related analogs), which it is developing for the treatment of hematological malignancies (non-Hodgkin’s lymphoma and multiple myeloma), and CB1089 (seocalcitol), an analog of vitamin D, which the Company is developing for the treatment of cancer. In July 2009, Johnson & Johnson completed the acquisition of Cougar Biotechnology with approximately 95.9% interest in Cougar Biotechnology's outstanding common stock.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/200912/31/2008YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
6770 Blank checks
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Director Alan H.Auerbach 39 5/1/2003 5/1/2003
Executive Vice President - Research and Development, Chief Medical Officer Arturo M.Molina 50 8/1/2008 5/1/2007
Senior Vice President - Finance, Treasurer Charles R.Eyler 61 9/22/2008 9/1/2004
6 additional Officers and Directors records available in full report.

Business Names
Business Name
CGRB
Cougar Biotechnology Inc.
Cougar Biotechnology Limited
Cougar Biotechnology, Inc

General Information
Number of Employees: 54 (As of 12/31/2008)
Outstanding Shares: 20,784,120 (As of 5/4/2009)
Shareholders: 3,097
Stock Exchange: NASD
Federal Tax Id: 202903204
Fax Number: (310) 943-8059


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023